(Circulation. 1997;96:1520-1524.)
© 1997 American Heart Association, Inc.
Articles |
Class Ia Antiarrhythmic Drug Cibenzoline
A New Approach to the Medical Treatment of Hypertrophic Obstructive Cardiomyopathy
From the Second Department of Internal Medicine, Ehime University School of Medicine, and Internal Medicine, Takanoko Hospital (T.O.), Ehime, Japan.
Correspondence to Mareomi Hamada, MD, The Second Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Onsen-gun, Ehime 791-02, Japan.
Background The class Ia antiarrhythmic drug disopyramide relieves the outflow tract obstruction of hypertrophic obstructive cardiomyopathy (HOCM). Disopyramide, however, has several adverse effects, such as dysuria and thirst, resulting from its anticholinergic activity. A new class Ia antiarrhythmic drug, cibenzoline, has little anticholinergic activity. The aim of this study is to elucidate whether cibenzoline attenuates left ventricular pressure gradient (LVPG) in patients with HOCM.
Methods and Results Ten patients with HOCM (mean age, 59±12 years) participated in this study. LVPG and left ventricular functions were measured before and 2 hours after administration of a single oral dose of 150 or 200 mg cibenzoline. LVPG decreased from 123±60 to 39±33 mm Hg (P=.0026). The E/A ratio in transmitral Doppler flow increased from 1.20±0.84 to 2.00±1.72 (P=.029). Isovolumic relaxation time increased from 73±16 to 101±23 ms (P=.0026). Left ventricular diastolic dimension remained unchanged, but left ventricular systolic dimension enlarged significantly, from 21.6±2.4 to 26.2±3.3 mm (P=.0004). Fractional shortening decreased from 47.6±6.1% to 34.6±8.8% (P=.0007). Left ventricular ejection time index decreased significantly, and preejection period index increased in all the patients. Decreased LVPG remained maintained even in the long-term treatment with cibenzoline.
Conclusions These results indicate that cibenzoline can markedly attenuate LVPG in patients with HOCM. A decrease in myocardial contractility seems to be closely related to a marked decrease in LVPG.
Key Words: antiarrhythmia agents • cardiomyopathy • contractility • echocardiography • hypertrophy
This article has been cited by other articles:
 |
|
 |
|
  Y. Hosokawa, H. Takano, T. Ohno, M. Takayama, and T. Takano Impact of Percutaneous Transluminal Septal Myocardial Ablation on Refractory Paroxysmal Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy Angiology, July 1, 2008; 59(3): 329 - 334. [Abstract] [PDF]
|
|
|
|
|
|
S.-i. Morimoto, A. Sugiura, M. Iwase, N. Kubo, S. Hiramitsu, A. Uemura, M. Ohtsuki, S. Kato, Y. Kato, and H. Hishida Relief of Left Ventricular Outflow Obstruction by Cibenzoline in a Patient With Fabry's Disease: A Case Report Angiology, March 1, 2006; 57(2): 241 - 245. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Sarkozy, A. Caenepeel, P. Geelen, P. Peytchev, M. de Zutter, and P. Brugada Cibenzoline induced Brugada ECG pattern Europace, January 1, 2005; 7(6): 537 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hiasa, M. Hamada, H. Saeki, A. Ogimoto, T. Ohtsuka, Y. Hara, and Y. Shigematsu Cardiac Sympathetic Nerve Activity Can Detect Congestive Heart Failure Sensitively in Patients With Hypertrophic Cardiomyopathy Chest, September 1, 2004; 126(3): 679 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hamada, Y. Shigematsu, K. Ohshima, J. Suzuki, A. Ogimoto, T. Ohtsuka, and Y. Hara Diagnostic Usefulness of Carotid Pulse Tracing in Patients With Hypertrophic Obstructive Cardiomyopathy Due to Midventricular Obstruction: A Comparison With Idiopathic Hypertrophic Subaortic Stenosis Chest, October 1, 2003; 124(4): 1275 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ashidagawa, M. Ohara, and Y. Koide An Intraoperative Diagnosis of Dynamic Left Ventricular Outflow Tract Obstruction Using Transesophageal Echocardiography Leads to the Treatment with Intravenous Disopyramide Anesth. Analg., February 1, 2002; 94(2): 310 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Dimitrow, K. Kodama-Takahashi, Y. Shigematsu, M. Hamada, K. Hiwada, Y. Kazatani, K. Matsuzaki, and E. Murakami Coronary Vasospasm in Hypertrophic Cardiomyopathy Chest, April 1, 2001; 119(4): 1289 - 1291. [Full Text] [PDF]
|
|
|
|
 |
|
 H.-W. Hopp, F. M. Baer, C. Ozbek, K. H. Kuck, B. Scheller, and for the AtheroLink Study Group A synergistic approach to optimal stenting: Directional coronary atherectomy prior to coronary artery stent implantation--the AtheroLink registry J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1853 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Li, H. Simon, T. M.A. Bocan, and J.T. Peterson MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition Cardiovasc Res, May 1, 2000; 46(2): 298 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tokudome, K. Mizushige, T. Ueda, S. Sakamoto, H. Matsuo, and K. Mizushige Effect of Disopyramide on Left Ventricular Pressure Gradient in Hypertrophic Obstructive Cardiomyopathy in Comparison with Propranolol: A Case Report Angiology, April 1, 1999; 50(4): 331 - 335. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Hahalis, D. Alexopoulos, A. S. Manolis, M. Hamada, Y. Shigematsu, K. Hiwada, Y. Hara, S. Ikeda, H. Okayama, K. Kodama, et al. Altered Mitral Flow Pattern in Patients With Hypertrophic Obstructive Cardiomyopathy • Response Circulation, November 10, 1998; 98 (19): 2098 - 2102. [Full Text] [PDF]
|
|